Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MICROB-PREDICT

Financiado

Cerrado

MICROBiome based biomarkers to PREDICT decompensation of liver cirrhosis and tre...

MICROBiome based biomarkers to PREDICT decompensation of liver cirrhosis and treatment response Decompensation of liver cirrhosis and progression towards acute-on-chronic liver failure (ACLF) causes 1.2 million deaths/year. Microbiome is causally involved in cirrhosis progression and is for drugs the first interaction point... ver más

31/03/2025

EF CLIF

15M€

Presupuesto del proyecto: 15M€

Líder del proyecto

EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC... No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 25 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-12-03

SC1-BHC-03-2018: Exploiting research outcomes and ap...

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

25 Participantes

EF CLIF

2.28M€ | Lider

ZYDOTRONIC

342.56K€ | Participante

UNIVERSITY COLLEGE LONDON

323.50K€ | Participante

KU Leuven

620.00K€ | Participante

Proyectos interesantes

LIVERAIM

Medical Technol...

Data Science

25M€ Cerrado

PoLiMeR

Medical Technol...

Data Science

4M€ Cerrado

Perseus MAP

Medical Technol...

Data Science

4M€ Cerrado

GALAXY

Medical Technol...

Data Science

6M€ Cerrado

BestTreat

Medical Technol...

Data Science

4M€ Cerrado

FLDcure

Medical Technol...

Data Science

150K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 75 meses Fecha Inicio: 2018-12-03
Fecha Fin: 2025-03-31

Líder del proyecto

EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC... No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 15M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Decompensation of liver cirrhosis and progression towards acute-on-chronic liver failure (ACLF) causes 1.2 million deaths/year. Microbiome is causally involved in cirrhosis progression and is for drugs the first interaction point with the patients. Drugs can alter the microbiome leading to unwanted effects or even facilitating their effects, but the microbiome metabolizes the drugs, shapes their effects and possibly determines the host response to drugs. As each person carries an individual microbiome, insight in these processes should help stratify or even personalize patient health care and treatment. The aims of MICROB-PREDICT are 1) to better understand the role of microbiome and the gut-liver-axis interactome with respect to microbiome functionalities, 2) to identify and validate microbiome-based biomarkers and signatures for personalized prediction of decompensation and ACLF, and response to treatment, 3) to design three new tests as easy-to-use tools and point-of-care, smartphone-connected nanobiosensors, and 4) to validate them in a randomized controlled trial. MICROB-PREDICT will assemble existing data and samples from major microbiome initiatives in hepatology (12 international studies, >10,000 patients), and enrich them with holistic and in-depth analysis using cutting-edge multi-omics technologies of host and microbiome from different body sites in samples of >1,000 patients collected in a longitudinal manner with sequential visits and controlling for confounders. MICROB-PREDICT results will foster more accurate, personalized risk stratification and significant steps towards personalized treatment of decompensated cirrhosis and ACLF. World-leading microbiome specialists, technology leaders and clinical experts make this a programme of scientific excellence; patient organisations (ELPA) and the European Association for the study of the Liver (EASL) will channel our results into a powerful dissemination, communication and exploitation programme.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores